Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Absci Corporation filings document a Nasdaq-listed clinical-stage biotechnology issuer developing generative AI-designed biologic therapeutics. Its 8-K reports furnish quarterly and annual financial results, business presentations, and internal pipeline updates for programs such as ABS-201 and the broader prolactin and PRLR portfolio.
Proxy and material-event filings cover board and shareholder matters, executive compensation and equity-plan governance, director and officer indemnification agreements, common stock registered on the Nasdaq Global Select Market, and amendments to material agreements related to prior corporate transactions.
Absci Corporation has priced an underwritten public offering of 13,495,277 shares of its common stock. The shares are being sold at $7.41 per share, for expected gross proceeds of about $100 million and estimated net proceeds of approximately $93.5 million after fees and expenses.
All shares are being sold by Absci under an effective shelf registration statement on Form S-3. The company plans to use the net proceeds primarily to advance ABS-201, its AI-designed anti-PRLR antibody program for androgenetic alopecia and endometriosis, and for working capital and general corporate purposes.
Absci Corporation is offering 13,495,277 shares of common stock at $7.41 per share. The prospectus supplement states that 5,398,111 of those shares have been allocated for purchase by Eli Lilly and Company for an aggregate offering price of $40 million. The underwritten offering is expected to deliver shares on or about June 25, 2026, and the company estimates net proceeds of approximately $93.5 million. The supplement cites 155,350,135 shares outstanding as of March 31, 2026 as the baseline for dilution calculations and discloses immediate dilution to new investors of $6.08 per share based on as adjusted net tangible book value.
Use of proceeds is stated as funding advancement of ABS-201 across androgenetic alopecia and endometriosis, working capital and general corporate purposes; timing and allocation remain at management’s discretion.
Absci Corporation reported positive interim Phase 1 results for ABS-201 from its HEADLINE trial in healthy adults with and without androgenetic alopecia. In four single ascending dose cohorts totaling 32 participants, intravenous ABS-201 at 150, 450, 900, and 1800 mg appeared well tolerated with no serious adverse events reported.
Most treatment-emergent adverse events were mild; one moderate headache was assessed as unlikely related to treatment. Interim pharmacokinetic data indicate an estimated half-life of at least 65 days, supporting a potential dosing schedule of two or three injections over six months. The study has advanced into a subcutaneous multiple ascending dose phase in androgenetic alopecia participants, with interim proof-of-concept data expected in the second half of 2026 and full proof-of-concept data in early 2027.
Absci Corp director Mary T. Szela received new equity awards as part of her compensation. She was granted 8,400 Restricted Stock Units, each representing one share of common stock, and 33,200 stock options with a per-share exercise price of $7.34.
The RSUs and options will vest in full on the earlier of the first anniversary of the grant date or Absci’s next annual stockholder meeting, provided she continues serving the company through that date. After these grants, she directly holds 8,400 RSUs and 33,200 options scheduled to expire on June 3, 2036.
Absci Corp director Karen K. McGinnis received new equity awards. She was granted 10,100 Restricted Stock Units, each representing one share of common stock, increasing her direct common stock holdings to 48,420 shares. She also received stock options for 39,800 shares at an exercise price of $7.34 per share.
Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or Absci’s next annual stockholders’ meeting, conditioned on her continuous service to the company.
Absci Corp director Mary T. Szela reported equity awards consisting of restricted stock units and stock options. She received 10,100 shares of Common Stock in the form of restricted stock units under the Absci Corporation 2021 Stock Option and Incentive Plan, with each unit representing one share.
She was also granted options over 39,800 shares of Common Stock at an exercise price of $7.3400 per share, expiring on June 3, 2036. Both the restricted stock units and the options vest in full on the earlier of the first anniversary of the June 4, 2026 grant date or the company’s next annual stockholder meeting, subject to her continuous service. Following these awards, her reported direct holdings are 10,100 shares of Common Stock and options over 39,800 shares.
Absci Corp director Menelas N. Pangalos received new equity awards. He was granted 10,100 Restricted Stock Units, each representing one share of common stock, and stock options for 39,800 shares at an exercise price of $7.34. Both awards vest in full on the earlier of the first anniversary of grant or Absci’s next annual stockholder meeting, subject to his continued service. After the RSU grant, he holds 242,408 common shares directly, plus the newly granted options.
Absci Corp director Frans Van Houten received new equity compensation consisting of restricted stock units and stock options. He was granted 10,100 RSUs, each representing one share of common stock, under the Absci Corporation 2021 Stock Option and Incentive Plan.
The RSUs vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, contingent on continued service. He also received stock options for 39,800 shares of common stock at an exercise price of $7.34 per share, vesting on the same schedule. Following the RSU grant, his direct common stock holdings total 73,420 shares.
Absci Corp director Daniel A. Rabinovitsj received new equity awards in the form of restricted stock units and stock options. He was granted 10,100 RSUs, each representing the right to receive one share of common stock. After this grant, he directly holds 33,420 common shares.
He was also granted options on 39,800 shares of common stock at an exercise price of $7.34 per share, expiring in 2036. Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or Absci’s next annual stockholder meeting, as long as he continues serving the company.
Absci Corp director Joseph Sirosh received new equity awards. He was granted 10,100 Restricted Stock Units, each representing one share of common stock, and a stock option for 39,800 shares at an exercise price of $7.34 per share.
The RSUs and options each vest in full on the earlier of the first anniversary of the grant date or Absci’s next annual stockholder meeting, as long as he continues serving the company. After the RSU grant, Sirosh directly holds 33,420 common shares, and he now also holds the new option award.